<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - In vitro diagnostic medical devices (A7-0327/2013 - Peter Liese) - Tuesday, 22 October 2013</title><meta name="title" content="Verbatim report of proceedings - In vitro diagnostic medical devices (A7-0327/2013 - Peter Liese) - Tuesday, 22 October 2013" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2013 - Source: European Parliament" /><meta name="available" content="22-10-2013" /><meta name="sipade-leg" content="7" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - In vitro diagnostic medical devices (A7-0327/2013 - Peter Liese) - Tuesday, 22 October 2013" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-7-2013-10-22-ITM-009-03_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-10-22-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-10-22-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-10-22-ITM-009-02_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-10-22-ITM-009-02_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-10-22_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-10-22_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2012/0267(COD)">2012/0267(COD)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A7-0327/2013</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-7-2013-0327_EN.html" class="ring_ref_link">A7-0327/2013</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p>
                        <a href="/doceo/document/PV-7-2013-10-22-ITM-004_EN.html" class="ring_ref_link">PV 22/10/2013 - 4</a><br />
                        <a href="/doceo/document/CRE-7-2013-10-22-ITM-004_EN.html" class="ring_ref_link">CRE 22/10/2013 - 4</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-7-2013-10-22-ITM-006-03_EN.html" class="ring_ref_link">PV 22/10/2013 - 6.3</a><br />
                        <a href="/doceo/document/CRE-7-2013-10-22-ITM-006-03_EN.html" class="ring_ref_link">CRE 22/10/2013 - 6.3</a><br />
                        <a class="ring_ref_selected">Explanations of votes</a><br />
                        <a href="/doceo/document/PV-7-2014-04-02-ITM-018-12_EN.html" class="ring_ref_link">PV 02/04/2014 - 18.12</a><br />
                        <a href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_EN.html?textTabled=A-7-2013-0327" class="ring_ref_link">Explanations of votes</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-7-2013-0427_EN.html" class="ring_ref_link">P7_TA(2013)0427</a><br />
                        <a href="/doceo/document/TA-7-2014-0267_EN.html" class="ring_ref_link">P7_TA(2014)0267</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Tuesday, 22 October 2013 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 9.3. In vitro diagnostic medical devices (<a href="/doceo/document/A-7-2013-0327_EN.html">A7-0327/2013</a> - Peter Liese) </td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:17:01&amp;playerEndTime=20131022-13:20:27" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:17:01&amp;playerEndTime=20131022-13:20:27" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:17:01&amp;playerEndTime=20131022-13:20:27" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td></tr></table>
<a name="2-202-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Oral explanations of vote</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-203-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28116.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:17:01&amp;playerEndTime=20131022-13:18:17" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marian Harkin (ALDE). -</span></span>   Madam President, I was happy to support this report because currently the legislation that ...</p>
<p class="contents"><span class="italic">(Interruption from the President)</span></p>
<p class="contents">I was happy to support this report because the legislation we currently have in place is not robust enough to fully ensure that low-quality, in vitro medical devices are not placed on the market. We have a duty with regard to patient safety; indeed, that is our first duty. But it is not our only duty. We also have to ensure that we have a streamlined, effective system which ensures new technologies get to market as soon as they are fully approved.</p>
<p class="contents">The principle of subsidiarity is also important, and the issue of prescription policies for class D devices should be at national level and not at EU level, in my view. This proposal regulates products’ safety, and not medical or other practices set out at national level.</p>
<p class="contents">Finally, I was fully supportive of the ALDE amendments put forward with our EPP colleagues, which aligned our position with that on the medical devices directive.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-204-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28117.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:18:25&amp;playerEndTime=20131022-13:19:28" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jim Higgins (PPE). - </span></span>  Madam President, while I welcome this regulation, which was the result of the French breast implant scandal, I would warn against knee-jerk legislation. I welcome the decision today to refer the report back to committee. When adopted, this regulation will replace the existing directive, and we hope it will address inconsistencies in Member States’ interpretation of current rules, thus increasing the protection of public health and safety and removing obstacles to the internal and external market.</p>
<p class="contents">Medical devices are a very large employer in my country, employing 25 000 people in total. My constituency, particularly Galway, is very dependent on this industry. Therefore it was important that this report not place unnecessary barriers on manufacturers. This is a highly sensitive and technical area. I welcome the opportunity to dedicate further time to this report in order to ensure that we get the balance right. Essentially we need to guarantee the highest level of consumer protection but also avoid placing unnecessary burdens on manufacturers.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-205-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23894.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:19:36&amp;playerEndTime=20131022-13:20:27" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Anna Záborská (PPE). - </span></span>  Návrh smernice reguluje trh s diagnostickými pomôckami používanými in vitro a pri stanovovaní, pri analyzovaní DNA. Ide o stanovenie minimálnych štandardov, napríklad aj pri používaní DNA testov. Dôležité je najmä to, že v budúcnosti by sa malo v celej Európskej únii zaviesť povinné poradenstvo kvalifikovanými pracovníkmi. Dôležitá je najmä otázka informovaného súhlasu, ktorý patrí k základným právam garantovaným v charte európskej únie. Len informovaní pacienti môžu prevziať zodpovednosť za často veľmi vážne rozhodnutia týkajúce sa ich života a zdravia.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-206-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Written explanations of vote</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-206-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96976.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Luís Paulo Alves (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Aprovo o presente relatório, tendo em consideração que a proposta da Comissão centra-se bastante na qualidade do produto. Contudo, há que salientar que os especialistas e muitas organizações internacionais, como o Conselho da Europa, a OCDE e a Sociedade Europeia de Genética Humana formularam reiteradamente a sua posição de que, em muitos casos, mais importante do que a qualidade do produto é o quadro em que o produto é aplicado. Especialmente no caso dos testes de ADN é extremamente importante respeitar o princípio do consentimento esclarecido. Isto também foi solicitado várias vezes pelo Parlamento Europeu. Assim, proponho alterações nesta matéria. É consensual que a União Europeia não deve pretender limitar o acesso dos doentes aos testes de ADN, mas que deve ser sempre facultado aconselhamento genético apropriado sobre as consequências, antes da realização do teste. Para respeitar o princípio da subsidiariedade, devem ser os Estados-Membros a regulamentar os pormenores, e os Estados-Membros devem ter a possibilidade de ir mais longe do que o exigido pelo regulamento.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-206-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28276.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Laima Liucija Andrikienė (PPE), </span></span>  <span class="italic">raštu</span><span class="bold">. − </span>Balsavau už rezoliuciją dėl diagnostikos <span class="italic">in vitro</span> medicinos prietaisų. Diagnostikos medicinos prietaisai (IVD) yra vieni iš svarbiausių medicinos prietaisų ir gali būti visų terapijų, įskaitant farmacijos produktus ir chirurgiją, pagrindas. Tinkama diagnostika yra esminis faktas ligų prevencijai ir efektyviam gydymui užtikrinti. Į rinką patekus žemos kokybės IVD padidėja rizika, kad tyrimų rezultatai bus klaidinantys ir pritaikytas gydymo metodas neatneš teigiamų rezultatų ar net sukels grėsmę paciento gyvybei. Kadangi minėtieji prietaisai gali laisvai cirkuliuoti bendrojoje ES rinkoje ir jiems nėra nustatytos nacionalinės sienos, privalome užtikrinti kuo didesnę saugą naudojant šiuos prietaisus. Kitaip tariant, šimtai tūkstančių įvairių tipų medicinos prietaisų, šiuo metu parduodamų Europos Sąjungos rinkoje – nuo pleistrų, švirkštų, kateterių ir kraujo mėginių ėmimo prietaisų iki įmantrių implantų ir gyvybės palaikymo technologijų – turi būti saugūs ne tik pacientams, bet ir sveikatos priežiūros specialistams, kurie juos naudoja arba tvarko, ir nespecialistams, kurie su jais turi sąlytį. Pritariu pranešėjo nuomonei, kad turi būti sugriežtinta šalių narių vykdoma kontrolė šių prietaisų naudojime ir patikrinimai gali būti vykdomi be išankstinio įspėjimo.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-207-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96702.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elena Oana Antonescu (PPE), </span></span>  <span class="italic">în scris</span><span class="bold">. − </span>Susţin propunerea de regulament care vizează consolidarea siguranţei pacientului în ceea ce priveşte dispozitivele medicale pentru diagnostic in vitro, prin care Parlamentul a cerut implicarea unui comitet de etică şi a introdus dispoziţii privind consimţământul informat şi consilierea genetică. Avem nevoie de norme mai stricte privind testele genetice. Este foarte important ca testările genetice să fie efectuate de personal medical calificat şi numai după ce pacientul şi-a dat consimţământul, fiind informat corespunzător. Este îngrijorător că există companii care oferă on-line efectuarea de teste ADN, de aceea legislaţia adoptată urmăreşte reguli mai stricte în acest domeniu. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-207-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96680.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zigmantas Balčytis (S&amp;D), </span></span>  <span class="italic">raštu</span><span class="bold">. − </span>Balsavau už šį siūlymą, kurio tikslas –sugriežtinti medicinos prietaisų kontrolę. Komisija yra pasiūliusi du skaidresnius ir labiau prie mokslo ir technologijų pažangos priderintus šios srities reglamentus: reglamentą dėl medicinos prietaisų ir reglamentą dėl <span class="italic">in vitro</span> diagnostikos medicinos prietaisų. Šiuo metu rinkoje yra daugiau kaip 500 tūkst. įvairių rūšių prietaisų, kurios vertė – maždaug 95 mlrd. eurų. Jie apima tokius produktus kaip pleistrai, kontaktiniai lęšiai, rentgeno aparatai, širdies stimuliatoriai, ŽIV kraujo testai ir kt. Pritariu siūlomoms taisyklėms, kuriomis bus patobulinti šie rinkoje esantys medicinos gaminiai, ir sugriežtinta <span class="italic">in vitro</span> diagnostikos medicinos prietaisų kontrolė, ypač po Europoje kilusio skandalo dėl nekokybiškų krūtų implantų ir klubo sąnario protezų. Pritariu siūlymams dėl griežtesnės nepriklausomų vertinimo įstaigų priežiūros, aiškesnių gamintojų, importuotojų ir platintojų teisių ir pareigų, išplėstos medicinos prietaisų duomenų bazės. Labai svarbu, kad būtų užtikrintas geresnis prietaisų atsekamumas visoje tiekimo grandinėje bei galimybė greitai ir veiksmingai reaguoti į saugos problemas.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-207-625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/5956.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Regina Bastos (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Os dispositivos médicos para diagnóstico <span class="italic">in vitro</span> são produtos que podem circular livremente no mercado comum. Não existem fronteiras nacionais para estes produtos no mercado europeu. É por esse motivo que a União Europeia tem a obrigação de assegurar o maior nível possível de segurança. Sem um diagnóstico correto não é possível um tratamento adequado nem a prevenção de doenças. Infelizmente a Diretiva em vigor não impede a comercialização de dispositivos de diagnóstico <span class="italic">in vitro</span> de baixa qualidade. No passado registaram-se casos em que um teste sida de baixa qualidade foi comercializado no mercado europeu com a marca CE. Neste sentido são propostas melhorias importantes para solucionar as insuficiências atuais do sistema, designadamente, o reforço do sistema de vigilância e fiscalização do mercado; a obrigatoriedade de inspeções não anunciadas às empresas; o reforço da supervisão dos Estados-Membros dos organismos notificados e a criação de uma rede de laboratórios de referência europeus que desempenha um papel importante no controlo de dispositivos médicos de risco elevado. Pelo exposto apoiei o presente relatório.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-207-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28214.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Bennahmias (ALDE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>J'ai approuvé aujourd'hui les deux rapports concernant la mise à jour des règlements relatifs aux dispositifs médicaux. Fin 2011, le scandale des implants mammaires défectueux PIP a révélé le manque de coopération entre États membres et le dysfonctionnement du système de traçabilité des dispositifs médicaux. Plus de 400 000 implants mammaires de la société française PIP ont en effet été commercialisés dans le monde en dépit du non-respect des critères de qualité. Aujourd'hui le Parlement s'est prononcé pour de nouvelles exigences: il s'agit d'améliorer la protection des patients en renforçant la traçabilité et les contrôles pour éviter un nouveau scandale de ce type. Cela passe notamment par le renforcement de l'accès aux données cliniques afin de mieux connaitre les produits mais aussi par la mise en place d'une "carte d'implant" pour les receveurs d'implants ou encore par un plus grand partage d'informations entre les autorités nationales. J'ai une inquiétude sur la question de l'accessibilité des tests à hauts risques: il ne faudrait pas que la nouvelle législation restreigne les possibilités pour les États membres de faciliter la disponibilité de tests (notamment dépistage HIV) au public (notamment à haut risque).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-207-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/38610.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Слави Бинев (EFD), </span></span>  <span class="italic">в писмена форма</span><span class="bold">. − </span>Подкрепих доклада на Петер Лизе относно ин витро диагностичните медицински изделия, защото настоящата директива не гарантира, че на пазара на Европейския съюз не се пускат нискокачествени ин витро диагностични медицински изделия. Смятам, че ЕС трябва своевременно да регулира тези въпроси и да предложи по-висока степен на безопасност предвид факта, че тези продукти се движат на свободния пазар на ЕС, включително и в България, която аз като евродепутат представлявам. </p>
<p class="contents">С промяната в директивата ще бъде укрепена системата за надзор на пазара, а нотифицираните органи ще бъдат значително подобрени. Подкрепям предложението за задължителни внезапни проверки на дружествата, както и въвеждането на мрежа от европейски референтни лаборатории, които да играят важна роля при контрола на високорисковите медицински изделия. Освен това съм за изцяло нова система за класификация, която е целесъобразна и се основава на международен консенсус.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29074.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vito Bonsignore (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>La relazione merita un voto favorevole per aver integrato la proposta della Commissione con contributi rilevanti, attenendosi ad alcuni principi importanti. </p>
<p class="contents">Nel testo coordinato rilevo infatti un solido approccio improntato al principio di libertà e sussidiarietà: sulle tecnologie sensibili sotto il profilo etico, a cominciare dal test DNA, sull'ampio spazio riservato agli ordinamenti nazionali, sulla previsione del comitato etico, sull'incardinamento dei poteri di verifica, sanzionatori e dissuasivi. Altrettanto equilibrato è l'approccio nel soddisfare le esigenze di sicurezza e protezione dei pazienti e le specificità tecnologiche e produttive del settore, in relazione al ruolo della ricerca e sviluppo. </p>
<p class="contents">Così, nel consentire margini di flessibilità nel rispondere ad emergenze mediche, nella disciplina dei fabbricanti (cominciando dalla declaratoria), nella definizione delle banche dati, nel sistema degli organismi certificati, nei termini ragionevoli di operatività del comitato etico, nella previsione sulla pubblicazione degli studi in maniera da favorire una domanda informata e responsabile e una corrispondente cultura industriale aperta e di eccellenza: qui mi pare sia in opera una robusta applicazione del principio di realtà. Ne risulta rafforzato l'obiettivo prioritario, che è quello di garantire nei limiti del ragionevole la protezione dei consumatori nell'esercizio del diritto alla salute, in un'ottica di trasparenza, consapevolezza e responsabilità. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96798.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">John Bufton (EFD), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>Against. My party voted against this report as it attempts to take HIV self-testing kits (as well as other virus testing kits including HPV, H1N1v) and mandatory genetic testing kits off the OTC market to make them prescription-only – this is good news for big pharmaceutical companies but bad news for everyone else.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-562"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96867.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Maria Da Graça Carvalho (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Congratulo-me com o relatório hoje aprovado pelo Parlamento Europeu especialmente pelo resultado alcançado. Visa o melhoramento da segurança do paciente. A questão da segurança dos cidadãos e das cidadãs europeus terá que vir em primeiro lugar e ser o centro das preocupações deste relatório.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-593"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/113597.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Minodora Cliveti (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. − </span>Avem nevoie la nivelul Uniunii Europene de consolidarea siguranței pacientului în ceea ce privește dispozitivele medicale pentru diagnostic in vitro (testele ADN, de diabetul zaharat, HIV, etc.). Fără un diagnostic corect nu putem asigura un tratament sau o prevenire adecvată a bolilor. Comisia a inclus îmbunătățiri majore pentru remedierea lacunelor actuale ale sistemului pentru dispozitivele medicale DIV. Organismele notificate vor fi îmbunătățite substanțial și va fi consolidată monitorizarea organismelor notificate de către statele membre. Cu toate acestea, o întărire mai puternică a sistemului propus va spori gradul de siguranță publică, monitorizarea și controlul întregului sistem de certificare. </p>
<p class="contents">Multe întreprinderi care oferă dispozitive medicale pentru diagnostic in vitro sunt IMM-uri. Prin amendamentele depuse, Parlamentul a ținut seama de capacitatea și nevoile IMM-urilor, precum și de necesitatea de a evita eforturi administrative disproporționate, costisitoare și nejustificate, însă fără compromiterea sănătății și a siguranței. </p>
<p class="contents">Consider, de asemenea, esențială cererea Parlamentului de implicare a unui comitet de etică și de introducere a dispozițiilor privind consimțământul informat și consilierea genetică deoarece este foarte important ca testările genetice să fie efectuate doar de personal medical calificat și numai după ce pacientul şi-a dat consimţământul, fiind informat corespunzător.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-601"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112788.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Birgit Collin-Langen (PPE), </span></span>  <span class="italic">schriftlich</span>. <span class="bold">− </span>Ich habe für den Bericht gestimmt, weil ich eine stärkere Kontrolle von Medizinprodukten nach den jüngsten Skandalen, wie zum Beispiel durch die schadhaften Brustimplantate der französischen Firma PIP, für dringend notwendig halte. Wir brauchen eine Regelung, die praxistauglich ist, mehr Patientensicherheit gewährleistet und gleichzeitig übertriebene Bürokratie verhindert. Ich finde es auch angebracht, dass zukünftig unangekündigte Kontrollen in den Betrieben durchgeführt werden können. Nur so können wir vermeiden, dass nach der Zulassung eines Medizinproduktes dieses durch minderwertige Produkte ausgetauscht wird.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-609"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96775.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Lara Comi (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>La salute costituisce uno dei beni più preziosi per ogni singolo individuo e per la collettività nel suo complesso, oltre ad essere un fattore determinante per la crescita e lo sviluppo economico. In questa prospettiva, l'introduzione di un quadro normativo volto a migliorare la sicurezza dei dispositivi medico-chirurgici in vitro e la trasparenza nel loro utilizzo e commercializzazione si configura come un passo avanti importante per l'innalzamento del livello di salute pubblica nell'ambito dell'Unione. Consumatori e operatori sanitari non potranno dunque che beneficiare da tale regolamento europeo. Per tale ragione ho espresso il mio voto favorevolmente.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/72775.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Rachida Dati (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>Grâce à ce texte, nous pouvons nous réjouir des ambitions européennes fortes en matière renforcement de la santé et de la sécurité de l'ensemble des patients européens ayant recours à un test in vitro. Ce texte prévoit une harmonisation des règles pour ces tests au sein de l'Union européenne, pour plus de transparence, au service de la protection de la santé des Européens.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-687"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4335.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marielle de Sarnez (ALDE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>Le scandale des prothèses mammaires PIP a mis en lumière les lacunes du système européen de contrôle des dispositifs médicaux. Ces produits, contrairement aux médicaments, ne nécessitent pas d'autorisation préalable de mise sur le marché d’une autorité sanitaire, il est donc indispensable de développer des règles de certification plus strictes, qui placent la sécurité des patients au premier plan. Avec la révision de ce système, les dispositifs médicaux présentant le plus de risques - comme ceux destinés à être implantés dans le corps humain-, seront désormais contrôlés par des organismes spécialisés. L'accès aux données cliniques des dispositifs permettra une meilleure surveillance du marché. Lorsqu'un incident se produit dans un État un système d'alerte favorisera une réaction rapide dans les autres pays européens. Le retraitement de certains dispositifs médicaux à usage unique peut exposer les patients à des risques sanitaires. Cette pratique est aujourd’hui interdite en France et les États qui le souhaitent pourront faire de même. Les dispositifs de diagnostic in vitro verront également leurs règles de sécurité renforcées par la mise en place, notamment, d’un comité d’éthique. Ces nouvelles mesures permettront de restaurer la confiance des consommateurs dans le secteur, tout en préservant sa capacité d'innovation.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4550.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jill Evans (Verts/ALE), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>I voted in favour of this report on in vitro diagnostic (IVD) medical devices. They are currently covered by a separate IVD Directive that is outdated due to the limited list of IVD that are considered ‘moderate’ and ‘high’ risk. Many IVD devices can be self-certified by the manufacturer without any third-party conformity assessment. The new proposal changes this and introduces a new risk classification to ensure these devices can be sold safely. In Wales we are very proud of being the birthplace of the NHS and we work to keep high standards of medical care. This legislation will help ensure that.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-812"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Göran Färm, Anna Hedh, Olle Ludvigsson, Jens Nilsson och Marita Ulvskog (S&amp;D), </span></span>  <span class="italic">skriftlig</span><span class="bold">. − </span>Vi svenska socialdemokrater välkomnar moderniseringen av EU:s regelverk för medicintekniska in vitro-produkter (IVDs). Människor ska kunna lita på att de produkter som finns på marknaden är ordentligt testade och säkra. Patientsäkerheten och folkhälsan fordrar att EU:s regelverk speglar den snabba utvecklingstakt som råder på marknaden. Nuvarande regelverk är föråldrat och har inte förnyats sedan 1990-talet. Detta har lett till stora skillnader i nationella regelverk mellan medlemsländer samt osäkerhet kring reglerna för vissa produkter.</p>
<p class="contents">Vi stöder att transparensen och informationsspridningen kring IVDs förbättras. För oss är det viktigaste att patienthälsan tryggas. Vi välkomnar särskilt det klassificeringssystem som introduceras för IVDs, då ett sådant också harmoniserar väl med EU:s generella regelverk för medicintekniska produkter. Utifrån textens utformning valde vi även att rösta för vissa ytterligare horisontella förändringar av regelverket, bland annat det nya tillsynssystem som föreslagits för anmälda organ.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96977.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Diogo Feio (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Os DIV são dispositivos médicos destinados a utilização fora do corpo humano <span class="italic">in vitro</span> e abrangem uma grande diversidade de testes, como o autoteste para a medição do nível de açúcar no sangue, testes de VIH e testes de ADN. Recorde-se que os DIV circulam livremente no espaço da UE e são já regulamentados por legislação europeia. Contudo, esta demonstrou algumas falhas que urge colmatar, sendo esse o objectivo da presente proposta, que apoio. Apoio por considerar fundamental que os DIV disponíveis no mercado europeu apresentem todas as condições de segurança e de qualidade, sem que tal imponha aos seus fabricantes requisitos de tal modo onerosos que afastem algumas PME do mercado. Encontro no relatório estas duas preocupações, o que muito me tranquiliza.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-208-937"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96899.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">José Manuel Fernandes (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>O relatório elaborado pelo colega Peter Liese debruça-se sobre a proposta de regulamento do Parlamento Europeu e do Conselho relativa aos dispositivos médicos para diagnóstico <span class="italic">in vitro</span>. Os dispositivos médicos <span class="italic">in vitro</span> são dispositivos médicos destinados à utilização fora do corpo humano, que podem ser utilizados em laboratório ou próximo do doente, como por exemplo o autoteste para a medição do nível de açúcar no sangue, testes de VIH e testes de ADN. Considerando que, sem um diagnóstico adequado, não é possível o tratamento adequado nem a prevenção de doenças, os dispositivos médicos <span class="italic">in vitro</span> revestem-se de grande importância. A atual diretiva não impede a comercialização dos dispositivos médicos de DIV de baixa qualidade e já foram identificados testes de VIH que informavam que não existia vírus, quando na verdade existia e facultavam muito mais resultados negativos falsos do que os demais testes disponíveis. Concordo assim com o reforço de um sistema de vigilância e de fiscalização do mercado, com as visitas de inspeção não anunciadas às empresas e com a criação de uma rede de laboratórios de referência europeus que desempenha um papel importante no controlo de dispositivos médicos de risco elevado.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-209-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96706.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">João Ferreira (GUE/NGL), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Os dispositivos médicos de diagnóstico <span class="italic">in vitro</span> (DIV) são dispositivos destinados a utilização fora do corpo humano (<span class="italic">in vitro</span>), que podem ser utilizados em laboratório ou próximo do doente, abrangendo uma grande diversidade de testes, como o auto-teste para a medição do nível de açúcar no sangue, testes de VIH e testes de ADN. Sem um diagnóstico adequado não é possível o tratamento adequado nem a prevenção de doenças. A diretiva em vigor não impede a comercialização de dispositivos médicos de DIV de baixa qualidade, existindo registo de casos em que um teste de HIV de baixa qualidade (com número anormalmente elevado de falsos negativos) foi comercializado no mercado europeu. Este relatório vem assegurar maior transparência e controlo nos dispositivos médicos, assim como uma maior proteção e informação aos pacientes, conferindo maior nível de segurança aos dispositivos médicos comercializados. O relatório propõe um novo sistema de classificação (tendo em conta o risco individual e de saúde pública), a introdução do conceito de consentimento esclarecido para testes genéticos (pré-natal e para doenças que se manifestam ao longo da vida adulta), aconselhamento genético, proteção de menores e pessoas com deficiência. Votámos favoravelmente.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-210-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/102886.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ildikó Gáll-Pelcz (PPE), </span></span>  <span class="italic">írásban </span><span class="bold">− </span>Támogattam a jelentést, ugyanis véleményem szerint szigorúbban kell szabályozni a DNS-vizsgálatokkal kapcsolatos tájékoztatást is, annak érdekében hogy a páciensek hozzájussanak a szükséges információkhoz. Úgy vélem, hogy genetikai teszteket csak megfelelő tájékoztatás után lehetne végezni, mivel ezek drámai következményekkel járhatnak a biztosítók és a munkavállalók számára. Nem utolsósorban pedig pszichológiai kockázatokat is magukban hordozhatnak. Mindent alaposan végig kell gondolnunk, hogy a lehető legtöbb rendelkezésre álló információ alapján dönthessen a páciens.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-210-125"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28208.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nathalie Griesbeck (ALDE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>Le vote de ces textes sur les dispositifs médicaux et sur les dispositifs médicaux de diagnostic in vitro est important puisque ces textes auront des répercussions directes sur la santé publique européenne et donc sur la vie quotidienne des citoyens de l'Union. À la suite de la série de scandales liés à la santé dont l'affaire des prothèses mammaires PIP, il m'apparait essentiel que la nouvelle législation comble les lacunes actuelles, renforce la protection des consommateurs et restaure la confiance des patients en la médecine. Les textes que j'ai votés soutiennent des mesures plus strictes en termes de surveillance, de certification et de traçabilité des dispositifs médicaux. Les contrôles seront dorénavant beaucoup plus rigoureux pour les dispositifs médicaux de diagnostic in vitro ou les autres. Nous avons également décidé de réglementer le retraitement des dispositifs à usage unique de façon à mieux assurer la sécurité des patients.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-210-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28117.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jim Higgins (PPE), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>While I welcome this Regulation, which was a result of the French breast implant scandal, I would warn against ‘knee-jerkʼ legislation which may hinder medical progress. That is why I welcome the referral of this report back to committee. Protection of consumers is paramount. Medical devices are a very large employer in Ireland, employing 25 000 people in total. My constituency, particularly Galway, is very dependent on this industry and it was therefore very important that this report not place unnecessary barriers on manufacturers. This is a highly sensitive and technical area. I welcome the opportunity to dedicate further time to this report to ensure that we get the balance right – essentially we need to guarantee the highest level of consumer protection, but also avoid placing unnecessary burdens on manufacturers, many of whom in Ireland are indigenous companies, or slowing down new life-saving products from making it to the market! Both Ireland and the EU need to protective their innovative edge. Currently, Europe has a competitive advantage over the US due to the speed with which companies can develop products.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-210-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96693.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Juozas Imbrasas (EFD), </span></span>  <span class="italic">raštu</span><span class="bold">. −</span> Balsavau už, kadangi bus geriau informuojami pacientai apie diagnostikos medicinos prietaisų naudojimą, kurių pagalba atliekami ŽIV, nėštumo arba DNR testai. Sustiprinus siūlomą sistemą padidės visuomenės saugumas, sugriežtės visos sertifikavimo sistemos priežiūra ir kontrolė.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-210-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96884.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Philippe Juvin (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>J'ai soutenu le rapport de mon collègue Peter Liese qui pose des standards de sécurité et de santé publique élevés pour les dispositifs médicaux in vitro ainsi que les organismes notifiés chargés de surveiller ces dispositifs médicaux. Nous avons néanmoins voté contre des restrictions sur les tests d’auto-diagnostic qui les auraient rendus disponibles uniquement par ordonnance. Le texte reprend également des dispositions adoptées pour le règlement sur les essais cliniques en cour de négociation. Je me félicite donc de sa très large adoption à 525 voix pour, 21 voix contre et 132 abstentions.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-211-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/102887.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Béla Kovács (NI), </span></span>  <span class="italic">írásban </span><span class="bold">− </span>Rengeteg jelenlegi úgynevezett civilizációs betegség köszönhető az élelmiszeriparnak, a környezeti ártalmaknak, a nem megfelelő életkörülményeknek. Kormányzati helyzetben minden lehetséges intézkedést megtennénk az állampolgáraink lelki és testi egészségének javítása érdekében. Mindemellett természetesen az orvostechnikai diagnosztikák minőségbiztosítása és fejlesztése is elengedhetetlen. Ez a jelentés az úgynevezett in vitro diagnosztikai orvostechnikai eszközökről szóló (pl. vércukorszintmérő, HIV-tesztek, DNS-vizsgálatok) irányelv felülvizsgálatával foglalkozik. Az érvényes irányelv nem biztosítja, hogy gyengébb minőségű in vitro diagnosztikai orvostechnikai eszközök ne kerüljenek forgalomba. Igen fontos, hogy erősödik a piacfelügyelet rendszere. Kötelezőek lesznek a társaságok előre be nem jelentett ellenőrzései. Ezenfelül a Bizottság az európai referencialaboratóriumok hálózatának bevezetését javasolja. A jelentés az egészségügyi ellátás javítását segíti, így azt megszavaztam. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-211-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96816.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Giovanni La Via (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>Ho espresso voto favorevole alla relazione perché ritengo sia necessario tutelare la salute di tutti i cittadini dell'Unione europea attraverso una migliore regolamentazione dei dispositivi medici IVD. I suddetti dispositivi, destinati a un uso diagnostico nell'ambito dell'HIV, del DNA o dell'epatite C, hanno bisogno di un maggior controllo affinché i test di bassa qualità non siano immessi sul mercato europeo. La relazione del collega on. Liese mira pertanto a regolamentare i parametri di sicurezza, qualità ed efficienza dei dispositivi medici facendo, dunque, un passo in avanti verso una proposta legislativa più chiara e affidabile.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-211-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1403.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">David Martin (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>I voted in favour of this report because it will still allow the UK to go ahead with new rules, which will mean that HIV tests will be available over the counter. This will be a progressive step forward in allowing those who suspect they may have contracted the disease to get tested much more easily. I hope this will result in a lowering in the number of people contracting the disease.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-212-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4462.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Clemente Mastella (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>I dispositivi medici medico-diagnostici in vitro (detti anche IVD) comprendono una vasta gamma di esami, compresi quelli autodiagnostici, come i test per l'HIV, i test del DNA e quelli per la misurazione della glicemia. </p>
<p class="contents">Noi condividiamo la proposta dell'onorevole Liese di apportare miglioramenti alla regolamentazione di tali dispositivi medici, essendo essi progenitori di tutte le terapie. Attualmente, purtroppo, la direttiva vigente non garantisce che non possano essere immessi sul mercato anche dispositivi IVD di bassa qualità e ciò rappresenta un danno potenziale per la tutela della salute di tutti i cittadini europei. </p>
<p class="contents">Tale proposta punta proprio a garantire la massima sicurezza nel mercato europeo, migliorando la vigilanza e la sorveglianza da parte degli organismi notificati, prevedendo inoltre l'introduzione di una rete di laboratori di riferimento specializzata nel settore. </p>
<p class="contents">Siamo infine concordi sul fatto che l'Unione europea non dovrebbe limitare l'accesso dei pazienti ai test del DNA ma, anzi, offrire una consulenza appropriata in materia genetica per informare sulle conseguenze prima dell'esecuzione del test, facendo propria la possibilità di poter adottare altre misure oltre a quelle richieste dal regolamento. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-212-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4412.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Véronique Mathieu Houillon (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>J'ai voté en faveur du rapport sur les dispositifs médicaux de diagnostic in vitro qui introduit des règles plus strictes concernant les tests génétiques, lesquels doivent être encadrés par des médecins ou des personnes qualifiées selon la loi nationale et avoir lieu après information et consentement explicite. J'ai voté contre la limitation des tests d'autodiagnostic sur prescription uniquement. En effet, j'estime que le test HIV, par exemple, doit pouvoir être délivré par une association, sans prescription.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-213-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96742.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Mélenchon (GUE/NGL), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>Les dispositifs médicaux in vitro sont des dispositifs médicaux destinés à un usage diagnostique en dehors du corps humain, c'est-à-dire dans un laboratoire ou à proximité du patient. Ils couvrent une très grande variété de tests, tels que des autodiagnostics pour la mesure du taux de glycémie, les tests HIV et les tests ADN. Le rapport propose diverses améliorations. Un nouveau système de classification selon le risque est proposé. Le système de surveillance du marché et de vigilance sera renforcé. Les inspections inopinées des entreprises seront obligatoires. Le rapport permet également l'instauration d'un réseau de laboratoires européens de référence. Le rapport ignore la question cruciale des conditions sociales et écologiques de production de ces dispositifs médicaux. En l'absence d'une telle harmonisation sociale, la libre circulation des dispositifs médicaux augmente les risques de délocalisation des fabricants. La France y est lourdement exposée puisqu'elle importe déjà 55 % des dispositifs médicaux consommés. Pourtant sa capacité de production continue de décliner, comme l'a montré la fermeture de l'usine Sodimedical. Je vote en faveur, pour appuyer les avancées normatives dans l'encadrement des produits. Mais je déplore une nouvelle étape de la libéralisation du marché des biens au détriment des travailleurs et de l'objectif de relocalisation des productions au plus près de leur consommation.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-213-625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96978.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nuno Melo (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Este relatório visa aprovar novas regras sobre os dispositivos de diagnóstico <span class="italic">in vitro</span>, usados em testes de gravidez, ADN ou HIV. Os dispositivos médicos de diagnóstico <span class="italic">in vitro</span> abrangem uma vasta gama de produtos, como testes de gravidez, testes de despistagem de HIV, testes de ADN, etc. Existem milhares de diferentes dispositivos com diferentes categorias de risco. As regras hoje aprovadas têm em vista garantir a segurança dos pacientes. Foram introduzidas novas regras sobre o consentimento dos pacientes sobre a utilização de um dispositivo para fins de testes genéticos, tendo sido aconselhada a criação de um comité de ética. As regras hoje aprovadas têm em vista garantir a segurança dos pacientes. Daí o meu voto favorável.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-213-687"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28407.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Willy Meyer (GUE/NGL), </span></span>  <span class="italic">por escrito</span><span class="bold">. − </span>He votado a favor del presente informe debido a que supone un incremento en los requisitos impuestos a las compañías del sector en el desarrollo de este tipo de equipamientos médicos. Los productos sanitarios para diagnóstico in vitro suponen una amplia variedad de dispositivos que pueden llegar a acarrear riesgos para la salud pública; desde test para medir la azúcar en sangre hasta para detectar el virus del VIH. Es por esto que esta nueva reglamentación propone una clasificación en función del riesgo e impone normas para que los productores mejoren la información disponible para el consumidor, así como se mejoran otros aspectos como la protección de los menores y de las personas incapacitadas, etc. He votado a favor del presente informe porque los requisitos impuestos reducen los riesgos de este tipo de dispositivos.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-213-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28178.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miroslav Mikolášik (PPE), </span></span>  <span class="italic">písomne</span><span class="bold">. − </span>Ďakujem spravodajcovi Petrovi Liesemu za vynikajúcu prácu na správe o diagnostických pomôckach in vitro, nakoľko bezpečná a kvalitná diagnostika je základným pilierom lekárskej starostlivosti. Potreba prísnejšej regulácie vyvstala najmä vzhľadom na nedostatočne preukázanú kvalitu viacerých testov HIV či DNA, ktorých nesprávne výsledky či interpretácia môžu mať až fatálne dôsledky. Európsky systém dohľadu je potrebný vzhľadom na to, že na európskom trhu pre tieto výrobky neexistujú žiadne národné hranice. Zvlášť oceňujem snahu o posilnenie etických záruk, najmä v otázke informovaného súhlasu, keď DNA testy nemôžu byť používané bez náležitého zodpovedného odborného genetického poradenstva s cieľom poskytnúť dostatočné informácie už pred uskutočnením testu.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-213-187"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96999.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alexander Mirsky (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>It is known that in vitro medical devices are devices intended for diagnostic purposes, i.e. tests which are carried out outside the human body. This product group covers a huge variety of tests, ranging from self-tests to measure blood sugar values, to HIV and DNA tests. The quality of such tests is crucial, as proper treatment is not possible without precise diagnosis. I am in favour.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-213-375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96695.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Radvilė Morkūnaitė-Mikulėnienė (PPE), </span></span>  <span class="italic">raštu</span><span class="bold">. − </span>Pritariu pozicijai, kad būtina užtikrinti pacientų saugumą, ypač atsižvelgiant į pastaraisiais metais įvykusius incidentus dėl nekokybiškų pacientų kūnuose naudojamų medicinos preparatų. Vis tik, kaip ir medicinos preparatų atveju, noriu atkreipti dėmesį, kad siūlomas teisinis reguliavimas turi ir trūkumų. Visų pirma – siūlomos patikros procedūros, mano nuomone, gali tapti neproporcingai sudėtinga ir brangia ribojančio pobūdžio priemone.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-213-562"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96760.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tiziano Motti (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>L'attuale quadro normativo per i dispositivi medico-diagnostici in vitro ha dimostrato certo i propri meriti, ma negli ultimi anni è anche stato oggetto di dure critiche. In un mercato interno cui partecipano 32 paesi e che registra progressi scientifici e tecnologici costanti, sono emerse notevoli differenze nell'interpretazione e nell'applicazione delle norme e questo compromette gli obiettivi principali della direttiva, che sono la sicurezza e le prestazioni degli DMD e la loro libera circolazione. La presente revisione mira a superare questi difetti e queste differenze e a rafforzare ulteriormente la sicurezza dei pazienti. Non possiamo quindi che accoglierla favorevolmente. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-213-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96653.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Katarína Neveďalová (S&amp;D), </span></span>  <span class="italic">písomne</span><span class="bold">. − </span>Zdravie a bezpečnosť diagnostický zariadení či pomôcok patrí medzi priority EÚ. Do tejto kategórie spadajú aj diagnostické pomôcky in vitro. Sú to zdravotnícke pomôcky určené na použitie pri diagnostike mimo ľudského tela, ktoré sa môže uskutočňovať v laboratóriu alebo v blízkosti pacienta, napríklad pri posteli. Spadá sem široká škála testov, ako je vlastné meranie cukru v krvi, testy na HIV a testy DNA. Diagnostické zdravotnícke pomôcky in vitro sú výrobky, ktoré sa voľne vyskytujú na spoločnom trhu. Aktuálna smernica avšak nezaručuje, že sa na trh nebudú uvádzať nekvalitné diagnostické zdravotnícke pomôcky takéhoto typu. Na Európsky trh sa dostal nekvalitný test na vírus HIV. Tento typ testu stanovil oveľa viac chybných negatívnych výsledkov ako iné dostupné testy na HIV. Čiže testy uvádzali neprítomnosť vírusu, hoci tam v skutočnosti bol. Tento produkt však bol pre pacientov v Európe k dispozícii niekoľko rokov. Existuje mnoho otázok, v ktorých Európska komisia navrhuje regulovať diagnostické zdravotnícke pomôcky in vitro rovnakým spôsobom ako ostatné zdravotnícke pomôcky. Na európskom trhu neexistujú pre tieto výrobky žiadne národné hranice. Preto je Európska únia povinná zaistiť najväčšiu možnú bezpečnosť.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-213-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96783.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Wojciech Michał Olejniczak (S&amp;D), </span></span>  <span class="italic">na piśmie</span><span class="bold">. − </span>Wyroby medyczne do diagnostyki in vitro obejmują rozmaite badania, takie jak samodzielne badanie poziomu cukru we krwi, badania na obecność wirusa HIV oraz testy DNA. Wniosek Komisji Europejskiej jest w dużej mierze skoncentrowany na jakości produktu. Wyeliminowanie z rynku powyższych wyrobów słabej jakości dotyczy ochrony zdrowia publicznego. W przeszłości zdarzały się sytuacje, w których wprowadzany był na rynek wyrób niskiej jakości i badania wykazywały wyniki ujemne, podczas gdy dana osoba była w rzeczywistości zarażona wirusem HIV. Było to zagrożenie dla zdrowia pacjentów przy transfuzjach krwi oraz wiązało się to z niebezpieczeństwem rozpowszechniania wirusa. Podobne sytuacje były zgłaszane w przypadku chorób zagrażających życiu, mianowicie zapalenia wątroby typu C. Te sytuacje pokazują bardzo ważną potrzebę wprowadzenia ulepszeń w systemie. Nowe usprawnienia dotyczące wyrobów medycznych do diagnostyki in vitro są podobne do tych, które wprowadzono dla innych wyrobów medycznych, i mają na celu polepszenie pracy jednostek notyfikowanych, wzmocnienie nadzoru rynku i systemu obserwacji. Uważam, że proponowane we wniosku utworzenie sieci europejskich laboratoriów referencyjnych pomoże wyeliminowaniu wyrobów medycznych, z którymi wiąże się wysokie ryzyko. W pełni popieram wprowadzenie nowych wniosków wraz z poprawkami, ponieważ uważam, że znacznie przyczyni się to do polepszenia bezpieczeństwa zdrowia pacjentów.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-213-906"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28279.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Justas Vincas Paleckis (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>The list of recent health scandals has become too long. It is important to stop these issues at the beginning, the diagnostic stage. Without a sufficient diagnostic there is no proper treatment or disease prevention. Low quality HIV tests placed on the common market are a good example of how a small diagnostic mistake can lead to major consequences. In the past these low quality tests have produced false negative results, leading the patient to believe he or she is virus free. Consequently, the misinformed, infected patient will unknowingly spread HIV. It is up to the EU to ensure the highest possible safety for these IVD medical devices because there are no national borders for these products. Further strengthening of the proposed system will only continue to enhance public safety. Unannounced visits in production facilities will hold manufacturers accountable and a central approval authority is a good option for preventing future scandals. Patient security and safety should always lie at the heart of our concerns, which is why I voted in favour of this report on in vitro diagnostic medical devices.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-213-937"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97197.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alfredo Pallone (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>La proposta di regolamento sui dispositivi medico-diagnostici in vitro (IVD) è un testo che va a regolare la produzione e l'utilizzo di tali dispositivi per migliorare la tutela dei pazienti e aumentarne la fiducia. </p>
<p class="contents">Bisogna garantire un alto livello di protezione della salute stimolando innovazione e concorrenza nel settore produttivo. In linea con il quadro programmatico di Orizzonte 2020 la relazione intende semplificare in un unico testo le tre direttive riguardanti l'argomento.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-214-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97050.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Antigoni Papadopoulou (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>In vitro medical devices (IVO) are intended for diagnostic use covering a huge variety of tests, including self-testing for measuring blood sugar, HIV or DNA, which freely circulate in the common market. A proper diagnostic test is a prerequisite for the proper treatment of patients or prevention of diseases. The current directive should ensure that low quality IVD medical devices are not sold on the market and that deficits in the existing regulation of IVD medical devices are improved. In the past, there have been several failings; low-quality HIV tests were placed on the European market, creating a huge amount of false negative results that endangered the lives of many patients, including a huge proportion of EU patients. What we want is patient safety and protection for all, based on some scientific evidence, high-quality specifications, strict quality control, fewer bureaucratic procedures, market surveillance, respect for ethnic values and continuous effective monitoring through the EU. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-214-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96902.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Maria do Céu Patrão Neves (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Os dispositivos médicos de DIV são, de acordo com a sua designação, meios de diagnóstico que não só podem ser manuseados por profissionais em contexto laboratorial, mas também pelo cidadão comum, em casa. Os DIV abrangem uma grande diversidade de testes, entram os quais se destacam, pela assiduidade do seu uso ou pelo potencial impacto dos resultados que ditam, os testes para medição do nível de açúcar no sangue, os testes para o VIH ou ainda os testes genéticos. Especificamente no que se refere aos testes genéticos, pela complexidade da sua plena interpretação e compreensão, pelo caráter potencialmente devastador dos seus resultados não necessariamente corretos, pelos impactos negativos em familiares que não procuraram nem desejaram qualquer informação genética, pela facilidade de utilização abusiva, importa estabelecer um quadro legislativo adequado que previna as consequências indesejáveis do recurso a estes DIV. Eis o que mais facilmente se pode garantir através da obrigatoriedade de aconselhamento genético prévio. No respeito pelo princípio da subsidiariedade, os Estados-Membros terão uma intervenção preponderante neste domínio na regulamentação nacional a partir do estabelecido a nível europeu.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-214-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/36392.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Aldo Patriciello (PPE), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>There is major concern over low quality IVD medical devices and HIV tests placed on the European market. Research has shown that these tests gave many more false negative results than other HIV tests available, which means the tests said that there was no virus but in fact there was. There is a life-threatening risk for European citizens who take the test if there is a blood transfusion which involves a false negative HIV result. People infected with HIV who receive a false negative test may put their partners at risk as well. Therefore, I voted in favour of this proposal to deal with this matter.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-214-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23693.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alojz Peterle (PPE), </span></span>  <span class="italic">pisno</span><span class="bold">. − </span>Glasoval sem za ojačeno varnost pacientov pri uporabi diagnostičnih medicinskih pripomočkih, ki se uporabljajo pri testih ugotavljanja nosečnosti, sladkorne bolezni ter HIV in DNK testiranja. Pozvali smo k vzpostavitvi odbora za etiko, ter uvedbi določb za informirano soglasje bolnikov in genetsko svetovanje. Strinjam se za začetek pogajanj s Svetom in bom še naprej podpiral predloge, ki dajejo paciente v svoje središče.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-215-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28409.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Raül Romeva i Rueda (Verts/ALE), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>In favour. IVD medical devices are medical devices intended for diagnostic use outside the human body (in vitro) which may be in a laboratory or near the patient, for example, at the bedside. It covers a huge variety of tests such as a self-testing for blood sugar measuring, HIV tests and DNA tests. IVD medical devices are products that can circulate freely in the common market. There are no national borders for these products in the European market. That is why it is an obligation for the European Union to ensure the highest possible safety. The proposal is based on Articles 114 and 168 of the Treaty. Article 114 calls for high levels of protection of human health. Article 168(4) (c) gives an additional specific legal base.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-215-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96755.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sergio Paolo Francesco Silvestris (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>Ho espresso parere favorevole, perché gli IVD sono dispositivi medici destinati a un uso diagnostico esterno al corpo umano (in vitro) ma molto importanti per esami di monitoraggio, screening e di diagnosi preliminare, come kit per la glicemia, test HIV e i test del DNA. L'immissione sul mercato di IDV di bassa qualità può creare gravi conseguenze a livello sanitario, non tanto per la diagnosi preliminare di falsi positivi, ma per la diagnosi di falsi negativi, che porterebbe a una diagnosi errata, con conseguenze serie, a esempio un test per HIV difettoso che conseguenze drammatiche potrebbe causare se il paziente in questione è un donatore di sangue. Per garantire la massima sicurezza possibile si adotterà un nuovo sistema di classificazione (A-D, A=dispositivo a basso rischio - D=dispositivo ad alto rischio). Molte delle società che producono tali dispositivi sono PMI, il regolamento terrà conto della capacità delle PMI di farsi carico di nuovi compiti, quindi mantenere questa situazione in linea di principio per le classi di rischio A, B e C ma di includere il rispetto dei requisiti quando si tratta di esami della classe D.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-216-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96655.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Monika Smolková (S&amp;D), </span></span>  <span class="italic">písomne</span><span class="bold">. − </span>Podporila som správu, lebo som presvedčená, že zmeny a navrhované opatrenia môžu výraznejším spôsobom posilniť a zlepšiť súčasný stav a systém pre diagnostické zdravotnícke pomôcky in vitro. Chápem, že v rámci obchodu s diagnostickými zdravotníckymi pomôckami in vitro sa uplatňovanie zásad voľného pohybu tovaru medzi členskými štátmi značne líši. Znepokojujúce je to, že na trh EÚ sa dostavajú často nekvalitné, životu nebezpečné diagnostické zdravotnícke pomôcky in vitro, ktoré ohrozujú nielen pacientov, používateľov, ale aj zdravotníckych pracovníkov. Myslím si, že bez ohľadu na to, či diagnostické zdravotnícke pomôcky in vitro budeme považovať za ,,malú sestru“ alebo za ,,rodiča“, v prvom rade musíme mať na zreteli bezpečnosť a ochranu ľudského zdravia. Aj keď v oblasti diagnostických zdravotníckych pomôcok in vitro, ktoré predstavujú širokú paletu výrobkov, sa za posledné obdobie dosiahlo viacero pozitívnych úspechov, očakávam, že v záujme odstránenia nedostatkov sa posilní systém dohľadu nad trhom, zlepší sa bezpečnosť verejnosti a dohľad nad celým systémom certifikácií a zavedie sa lepší systém pre pomôcky z najrizikovejších tried.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-217-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4545.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Catherine Stihler (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>I voted in favour of in vitro diagnostic medical devices because I support tougher rules on medical devices rather than supporting industry.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-218-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96920.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Kay Swinburne (ECR), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>I fully support these efforts to evaluate, here in the European Parliament, what we can do to improve patient health and safety, as this goal should be a priority for all MEPs. However, I do have reservations with regard to some measures outlined in this proposal, which I am concerned may place obstacles in the way of innovation without the assurances that patient safety will be improved.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-219-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29579.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marc Tarabella (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>La proposition de la Commission se concentre beaucoup sur la qualité des produits. Or, les experts et de nombreuses organisations internationales, comme le Conseil de l'Europe, l'OCDE et la Société européenne de génétique humaine, ne cessent d'affirmer que dans de nombreux cas, le cadre dans lequel le produit est appliqué est encore plus important que la qualité du produit. Dans le cas des tests ADN, en particulier, il est très important de respecter le principe du consentement éclairé. Le Parlement européen en a lui aussi fait la demande à plusieurs reprises. Un avis juridique conclut qu'il est possible et opportun d'introduire un texte correspondant dans la proposition. Dès lors, le rapporteur propose des amendements sur cette question. Il y a un consensus sur le fait que l'Union européenne ne devrait pas s'efforcer de limiter l'accès des patients aux tests ADN mais qu'un conseil génétique approprié devrait être systématiquement proposé pour les informer des conséquences du test avant son exécution. Pour respecter le principe de subsidiarité, les États membres devraient avoir la possibilité de régler les modalités et d'aller plus loin que ce que requiert le règlement. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-219-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96974.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nuno Teixeira (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Esta proposta de regulamento visa substituir a Diretiva relativa aos dispositivos médicos para diagnóstico <span class="italic">in vitro</span>, tendo sobretudo em consideração a incoerência das interpretações das regras actuais nos Estados-Membros, e, ao mesmo tempo, a protecção da segurança e saúde públicas e a eliminação de obstáculos ao funcionamento do mercado interno. Assim, pretende-se um alargamento e uma clarificação do âmbito de aplicação da legislação, o alinhamento das definições pelas práticas internacionais, a criação de um Grupo de Coordenação dos Dispositivos Médicos, entre outras medidas, tendo em conta que os dispositivos médicos para diagnóstico <span class="italic">in vitro</span> são dispositivos médicos destinados a utilização fora do corpo humano e que abrangem uma grande diversidade de testes, como o autoteste para a medição do nível de açúcar no sangue, testes de VIH e testes de ADN. Pelos motivos expostos, votei a favor do documento.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-219-375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96858.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marie-Christine Vergiat (GUE/NGL), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>J'ai voté en faveur de ce rapport mettant à jour une précédente directive relative aux dispositifs médicaux de diagnostic in vitro (DIV). Ces dispositifs sont destinés à effectuer un diagnostic en dehors du corps humain, c'est-à-dire dans un laboratoire ou au chevet du patient (autodiagnostics pour la mesure du taux de glycémie, tests HIV, tests ADN, etc.). La directive actuelle ne garantit pas que les dispositifs médicaux DIV de faible qualité soient écartés du marché. Or, comme il s'agit de produits qui peuvent circuler librement sur le sacro-saint marché commun, il paraissait important de remédier aux lacunes actuelles. Le système de surveillance du marché et de vigilance sera désormais renforcé, avec des inspections inopinées obligatoires. Ce rapport introduit également la notion de "consentement éclairé" comme condition pour les tests notamment prénataux ou génétiques : désormais, un conseil génétique approprié devra être systématiquement proposé pour informer les patients des conséquences avant l'exécution du test. Comme pour le rapport Roth-Behrendt, je resterai avec le groupe de la GUE vigilante lors des négociations à venir avec le Conseil sur cette directive.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-219-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97016.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Angelika Werthmann (ALDE), </span></span>  <span class="italic">schriftlich</span>. <span class="bold">− </span>Die Sicherheit und Präzision von In-vitro-Diagnostika muss garantiert werden können, eine verstärkte Kontrolle zur Verhinderung einer Verwendung von qualitativ minderwertigen Tests ist daher sehr zu begrüßen, insbesondere im Hinblick auf eine korrekte Diagnose von Krankheiten. Das Konzept der Einwilligung nach Aufklärung (informed consent) bei klinischen Studien darf nicht aufgeweicht werden, sondern sollte nach wie vor dem Patientenschutz dienen. Ich habe mich der Schlußabstimmung enthalten.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-220-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/35743.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Glenis Willmott (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>British Labour MEPs raised concerns with the rapporteur that specifying that Class D devices should be available on prescription only would prevent the UK from going ahead with plans to make HIV tests available over-the-counter. Although Labour MEPs are glad that the rapporteur agreed that Member States can make the decision to allow Class D devices without a prescription, we voted against all these amendments to harmonise prescription policy. Labour MEPs feel Member States should be free to decide on which prescription policies work best in favour of public health. In the case of HIV, many at-risk groups may not feel willing or able to discuss the issue with their doctor. Whilst counselling and advice should always be available, it is vital that we increase access to testing, given that one in four people living with HIV do not know that they have it. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-221-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96802.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jacek Włosowicz (EFD), </span></span>  <span class="italic">na piśmie</span><span class="bold">. − </span>Wyroby medyczne do diagnostyki in vitro są klasyfikowane zależnie od potencjalnego ryzyka związanego z ich stosowaniem: zamieszczone w wykazie A, zamieszczone w wykazie B, wyroby medyczne do diagnostyki in vitro do samodzielnego stosowania, wyroby medyczne do diagnostyki in vitro do oceny działania oraz pozostałe wyroby medyczne do diagnostyki in vitro. Wyrób medyczny do diagnostyki in vitro do samodzielnego stosowania jest to wyrób medyczny do diagnostyki in vitro przeznaczony przez wytwórcę do użytku przez nieprofesjonalistę w warunkach domowych. Wyrób medyczny do diagnostyki in vitro przeznaczonym do oceny działania jest to wyrób medyczny do diagnostyki in vitro przeznaczony do jednego lub większej liczby badań oceniających jego działanie, wykonywanych w laboratoriach analityki medycznej lub w innych odpowiednich miejscach poza przedsiębiorstwem wytwórcy.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-221-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/111589.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Inês Cristina Zuber (GUE/NGL), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Os dispositivos médicos de diagnóstico <span class="italic">in vitro</span> (DIV) são dispositivos destinados a utilização fora do corpo humano <span class="italic">in vitro</span>, que podem ser utilizados em laboratório ou próximo do doente, abrangendo uma grande diversidade de testes, como o auto-teste para a medição do nível de açúcar no sangue, testes de VIH e testes de ADN. A diretiva em vigor não impede a comercialização de dispositivos médicos de DIV de baixa qualidade, existindo registo de casos em que um teste de HIV de baixa qualidade (com número anormalmente elevado de falsos negativos) foi comercializado no mercado europeu. Este relatório vem assegurar maior transparência e controlo nos dispositivos médicos, assim como uma maior proteção e informação aos pacientes, conferindo um maior nível de segurança aos dispositivos médicos comercializados. Votámos favoravelmente.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
